Oxybutynin

Generic Name: Oxybutynin

Brand Names: Ditropan, Gelnique, Kentera, Oxytrol, Kentera (previously Oxybutynin Nicobrand)

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₃₁NO_₃

CAS Number: 5633-20-5

Unique Ingredient Identifier: K9P6MC7092

Background: Overactive bladder (OAB) is a common condition negatively impacting the lives of millions of patients worldwide. Due to its urinary symptoms that include nocturia, urgency, and frequency, this condition causes social embarrassment and a poor quality of life.
...

Indication: Oxybutynin is indicated for the symptomatic treatment of overactive bladder, which causes urge urinary incontinence and frequency, and urgency. Oxybutynin may also be used for children aged 6 and above for the symptomatic management of detrusor muscle overactivity which has been found to be related to a neurological condition. Spina bifida is an example of a...

Associated Conditions: Bladder Spasms, Detrusor Hyperreflexia, Overactive Bladder Syndrome (OABS)

Associated Therapies: -

Clinical Trials

Treatment of Hyperhidrosis With Oxybutynin

Phase 3

Completed

Conditions: Hyperhidrosis

Interventions: Drug: Placebo
Drug: Oxybutynin

First Posted Date: 2013-05-16

Last Posted Date: 2014-07-08

Lead Sponsor: University Hospital, Brest

Target Recruit Count: 62

Registration Number: NCT01855256

Locations: 🇫🇷
CHG de Morlaix, Morlaix, France
🇫🇷
Hospital, Brest, Brest, France
🇫🇷
CHG Landerneau, Landerneau, France

and more 1 locations

Botox Versus Oxybutynin as First Line Treatment for the Poorly Compliant Pediatric Neurogenic Bladder

Phase 3

Completed

Conditions: Neurogenic Bladder

Interventions: Drug: Botulinum Toxin A injection
Drug: Oxybutynin

First Posted Date: 2012-10-30

Last Posted Date: 2012-10-30

Lead Sponsor: Lawson Health Research Institute

Target Recruit Count: 20

Registration Number: NCT01716624

Locations: 🇨🇦
London Health Sciences Centre - Victoria Hospital, London, Ontario, Canada

A Study To Find Out How Fesoterodine Works In Children Aged 6 To 17 Years With Bladder Overactivity Caused By A Neurological Condition

Phase 3

Completed

Conditions: Urinary Bladder, Neurogenic

Interventions: Drug: Fesoterodine PR 4 mg
Drug: Fesoterodine PR 8 mg
Drug: Fesoterodine BIC 2 mg
Drug: Fesoterodine BIC 4 mg
Drug: Oxybutynin
Drug: Fesoterodine PR

First Posted Date: 2012-03-19

Last Posted Date: 2021-02-02

Lead Sponsor: Pfizer

Target Recruit Count: 181

Registration Number: NCT01557244

Locations: 🇧🇪
Hôpital Universitaire des Enfants Reine Fabiola, Bruxelles, Bruxelles-capitale, Belgium
🇯🇵
Kanagawa Children's Medical Center, Yokohama, Kanagawa, Japan
🇯🇵
Fukuoka Children's Hospital, Fukuoka-shi, Fukuoka, Japan

and more 80 locations

A Comparison Study of Oxybutynin and Botulinum Toxin for Neurogenic Detrusor Overactivity

Not Applicable

Completed

Conditions: Spinal Cord Injury

Interventions: Drug: Oxybutynin
Drug: Botulinum toxin A

First Posted Date: 2011-11-22

Last Posted Date: 2011-11-22

Lead Sponsor: Centro de Reabilitação e Readaptação Dr. Henrique Santillo

Target Recruit Count: 68

Registration Number: NCT01477736

Locations: 🇧🇷
UNICAMP, Division of Urology, Campinas, Sao Paulo, Brazil

Comparison of Solifenacin and Oxybutynin in the Treatment of Overactive Bladder

Phase 4

Conditions: Overactive Bladder

Interventions: Drug: Solifenacin
Drug: Oxybutynin

First Posted Date: 2011-08-26

Last Posted Date: 2011-08-26

Lead Sponsor: Adana Numune Training and Research Hospital

Target Recruit Count: 500

Registration Number: NCT01423838

Locations: 🇹🇷
Turkish Republic Ministry of Health Adana Numune Training and Research Hospital, Adana, Turkey

Use of Oxybutynin for Treating Hyperhidrosis: A Placebo-control Study

Phase 4

Completed

Conditions: Hyperhidrosis

Interventions: Drug: Oxybutynin
Drug: placebo

First Posted Date: 2011-03-08

Last Posted Date: 2011-09-22

Lead Sponsor: University of Sao Paulo

Target Recruit Count: 50

Registration Number: NCT01310712

Locations: 🇧🇷
Hospital das Clinicas da FMUSP, Sao Paulo, Brazil

Safety and Efficacy Evaluation of Oxybutynin Topical Gel In Children With Neurogenic Bladder

Phase 4

Completed

Conditions: Overactive Detrusor
Neurogenic Bladder

Interventions: Drug: Oxybutynin
Drug: Placebo

First Posted Date: 2010-09-01

Last Posted Date: 2024-01-17

Lead Sponsor: AbbVie

Target Recruit Count: 19

Registration Number: NCT01192568

Locations: 🇺🇸
Loma Linda University /ID# 236889, Loma Linda, California, United States
🇺🇸
Albany Medical College /ID# 236880, Albany, New York, United States
🇺🇸
Duke University /ID# 237494, Durham, North Carolina, United States

and more 7 locations

A Study to Compare Two Medications With an Inactive Medication and Look at the Effect on a Person's Mental Ability

Phase 4

Completed

Conditions: Cognition

Interventions: Drug: Solifenacin
Drug: Placebo
Drug: Oxybutynin

First Posted Date: 2010-05-19

Last Posted Date: 2012-10-15

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 26

Registration Number: NCT01126424

Use of Oxybutynin to Treat Axillary Hyperhidrosis

Not Applicable

Completed

Conditions: Axillary Hyperhidrosis
Osmidrosis

Interventions: Drug: Oxybutynin
Drug: Placebo

First Posted Date: 2010-05-06

Last Posted Date: 2010-05-06

Lead Sponsor: Grupo de Cirurgia Vascular

Target Recruit Count: 100

Registration Number: NCT01118429

Locations: 🇧🇷
Hospital das Clinicas da FMUSP, Sao Paulo, Brazil

The Effect of Extended-Release Oxybutynin Chloride on Vasomotor Symptoms in Healthy Post-Menopausal Women

Phase 2

Completed

Conditions: Menopause
Hot Flashes

Interventions: Drug: Oxybutynin chloride
Drug: Placebo

First Posted Date: 2009-10-07

Last Posted Date: 2012-12-12

Lead Sponsor: Ortho-McNeil Janssen Scientific Affairs, LLC

Target Recruit Count: 148

Registration Number: NCT00990886

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy